OakChart

Mira Pharmaceuticals Inc

MIRAHealthcare·Drug Manufacturers - General·USA·Nano·NASD·Nov 11 • 3:58 PM ET

0.6221+0.0012 (0.19%)
2026-11-12 03:21 CET
Market cap
26.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-31.04 USD m
Free cash flow, TTM
-4.64 USD m
EPS diluted, TTM
-1.38
P/E
-
Compare

Price

MIRA against its 20, 50 and 200-day averages
2050200earnings
0.600.801.001.2014.6M29.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MIRAclose 0.6220-day 0.5950-day 0.70200-day 0.930.6252w low

63.2% under the 52-week high of 1.69 on 19 Dec 2025. 52-week low 0.51 on 30 Oct 2026. Last 15 sessions, 43.1% high to low

Volume 0.09× normal · the line is the 50-bar volume average

Profile

MIRA
52-week range, 10% of the way up
0.511.69

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Employees2
IPOAug 03, 2023
Beta1.59
ATR, 14d0.06
Rel volume0.09
Short float0.73%
Insider own7.92%
Inst own5.79%

Snapshot

6 groups

Valuation

Index-
Market Cap26.14M
Enterprise Value18.03M
Income-31.04M
Sales0.00M
Book/sh0.19
Cash/sh0.19
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2
IPOAug 03, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.20
P/C3.22
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio200.08
Current Ratio200.08
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.38
EPS next Y-0.12
EPS next Q-0.03
EPS this Y-
EPS next Y-
EPS next 5Y32.70%
EPS past 3/5Y-41.42% -211.56%
Sales past 3/5Y- -
EPS Y/Y TTM-186.73%
Sales Y/Y TTM-
EPS Q/Q68.18%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own7.92%
Insider Trans0.00%
Inst Own5.79%
Inst Trans0.54%
ROA-684.27%
ROE-710.85%
ROIC-380.24%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.90%
SMA50-11.70%
SMA200-33.16%
Trades-

Technical

Shs Outstand42.02M
Shs Float38.69M
Short Float0.73%
Short Ratio0.48
Short Interest0.28M
52W High1.69 -63.19%
52W Low0.51 21.98%
Volatility9.07% 9.79%
ATR (14)0.06
RSI (14)49.35
Beta1.59
Rel Volume0.09
Avg Volume594.00K
Volume52,550

Performance

Perf Week10.89%
Perf Month-6.65%
Perf Quarter-17.06%
Perf Half Y-35.93%
Perf YTD-58.80%
Perf Year-57.10%
Perf 3Y-58.80%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price6.50
Prev Close0.62
Price0.62
Change %0.19%

Peers

Mkt cap
TickerCompanyMkt cap
SCLXScilex Holding Company11.40M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
SKYESkye Bioscience Inc4.06M
TNXPTonix Pharmaceuticals Holding Corp75.20M
NRXPNRX Pharmaceuticals Inc106.50M
ARTLArtelo Biosciences Inc1.20M
MTRIMentari Therapeutics Inc8.57M
ALZNAlzamend Neuro Inc6.32M
CRDLCardiol Therapeutics Inc121.87M
VRTXVertex Pharmaceuticals Inc138.69B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide (GlobeNewswire)
  • MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study (GlobeNewswire) -7.76%
  • MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review (GlobeNewswire) +5.52%
  • MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND (GlobeNewswire) +11.66%
  • MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 (GlobeNewswire)
  • MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies (GlobeNewswire)
  • MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain (ACCESSWIRE)
  • MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction (ACCESSWIRE)
  • MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC (ACCESSWIRE)
  • MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
  • MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 (ACCESSWIRE)
  • MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN (ACCESSWIRE) +18.58%
  • Tapestry patents AI data analytics tech (Retail Dive)
  • MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.030--0.0300.00--
2025Q32025-12-03-1.180-1.180-1.1770.000.001
2025Q22025-09-03-0.090-0.100-0.000.002
2025Q12025-05-28-0.110-0.130-0.1070.000.002
2024Q42025-02-26-0.175-0.180-0.1470.000.003
2024Q32024-11-27-0.140-0.153-0.1360.000.003
2024Q22024-08-28-0.110-0.113-0.1140.000.003
2024Q12024-05-29-0.120-0.090-0.0870.000.002
2023Q42024-02-28-0.370-0.230-0.3920.000.001
2025Q4---0.040-0.143-0.001
2026Q3---0.030---1
2026Q4---0.030---1
2027Q1---0.040---1
2027Q2---0.040---1
2027Q3---0.040---1
2027Q4---0.040---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-0.640-0.680-0.6450.000.00
2024FY-0.525-0.553-0.000.00
2025FY--1.170-1.351-0.00
2026FY--0.180--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2025-12-031000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00
2026Q3S2025-10-311000.000.000.00
2026Q3S2025-10-301000.000.000.00

Estimate history

EPS, annual-0.005-0.148-0.478-0.645-0.509-1.351-1.3763
Period202020212022202320242025TTM
EPS, quarterly-0.114-0.136-0.147-0.107-0.091-1.177-0.143-0.027-0.029
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual14.74514.74514.78114.78116.56141.93942.022
Period202020212022202320242025MRQ
Shares, quarterly14.78116.26616.56116.81417.38539.51141.93942.02242.022
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other9.4010.498.028.537.051.450.07
Research and Development2.141.723.311.572.350.680.01
Other Operating Expense0.000.000.000.000.000.700.00
Operating Income-9.40-10.49-8.02-8.53-7.05-2.15-0.07
Interest Expense0.000.000.003.460.010.020.00
Unusual Expense0.210.040.000.000.000.000.00
Net Income Before Taxes-9.48-10.44-7.85-11.98-7.06-2.18-0.07
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-31.04-32.00-7.85-11.98-7.06-2.18-0.07
Net Income From Continuing Operations-31.04-32.00-7.85-11.98-7.06-2.18-0.07
Net Income-31.04-32.00-7.85-11.98-7.06-2.18-0.07
EPS (Recurring)-0.74-1.35-0.51-0.65-0.48-0.15-0.00
EPS (Basic, Before Extraordinaries)-1.38-1.35-0.51-0.65-0.48-0.15-0.00
EPS (Diluted)-1.38-1.35-0.51-0.65-0.48-0.15-0.00
EBITDA-9.40-10.49-8.02-8.53-7.05-2.15-0.07
Non-Operating Income (Expense)0.140.090.170.000.000.000.00
Other After Tax Adjustments-21.56-21.560.000.000.000.000.00
Stock Option Compensation Expense4.816.131.922.551.30--
Shares Outstanding42.0241.9416.5614.7814.7814.7514.75
Market Capitalization26.1426.1418.8815.5215.52--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other1.161.105.821.321.551.812.442.08
Research and Development0.710.520.500.410.500.310.861.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.16-1.10-5.82-1.32-1.55-1.81-2.44-2.08
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.090.090.21-0.180.000.000.000.00
Net Income Before Taxes-1.21-1.15-5.98-1.14-1.54-1.78-2.40-2.04
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.21-1.15-5.98-22.69-1.54-1.78-2.40-2.04
Net Income From Continuing Operations-1.21-1.15-5.98-22.69-1.54-1.78-2.40-2.04
Net Income-1.21-1.15-5.98-22.69-1.54-1.78-2.40-2.04
EPS (Recurring)-0.03-0.03-0.14-1.18-0.09-0.11-0.15-0.14
EPS (Basic, Before Extraordinaries)-0.03-0.03-0.14-1.18-0.09-0.11-0.15-0.14
EPS (Diluted)-0.03-0.03-0.14-1.18-0.09-0.11-0.15-0.14
EBITDA-1.16-1.10-5.82-1.32-1.55-1.81-2.44-2.08
Non-Operating Income (Expense)0.040.040.050.000.010.020.040.04
Other After Tax Adjustments0.000.000.00-21.560.000.000.000.00
Stock Option Compensation Expense0.020.024.470.300.490.870.550.27
Shares Outstanding42.0242.0241.9439.5117.3916.8116.5616.27
Market Capitalization26.1444.8163.2325.9321.0416.2318.8819.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments11.032.834.600.352.810.00
Short Term Receivables0.000.000.010.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.030.050.240.000.000.00
Total Current Assets11.062.894.860.352.810.00
Net Property, Plant & Equipment0.000.000.010.360.000.00
Total Investments and Advances0.000.000.000.000.000.00
Long-Term Note Receivable0.040.040.07-0.000.01
Intangible Assets0.000.000.000.00--
Other Assets0.000.000.000.140.550.02
Total Assets11.092.924.930.863.360.03
Short Term Debt Incl. Current Port. of LT Debt0.000.000.010.410.290.09
Accounts Payable0.130.720.540.000.000.00
Other Current Liabilities0.570.000.010.960.800.00
Total Current Liabilities0.700.720.561.371.090.09
Long Term Debt0.000.000.000.080.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.700.720.561.451.090.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.392.204.37-0.602.26-0.06
Total Shareholders Equity10.392.204.37-0.602.26-0.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.392.204.37-0.602.26-0.06
Total Liabilities & Stockholders Equity11.092.924.930.863.360.03
Book Value Per Share0.250.130.30-0.040.15-0.00
Tangible Book Value Per Share0.250.130.30-0.040.15-0.00
Full-Time Employees253---
Price to Book Ratio3.205.191.911.91--
Return on Assets-456.59-199.93-413.86-335.05-128.66-
Return on Equity-508.28-238.90-634.30-847.77-197.93-
Return on Invested Capital-307.94-356.98-273.92--96.25-
Quick Ratio15.753.998.700.262.570.04
Current Ratio15.753.998.700.262.570.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-9.48-10.44-7.85-11.98-7.06-2.18-0.07
Other Funds (Non Cash)5.296.351.926.991.310.020.00
Funds from Operations-4.19-4.09-5.93-4.99-5.75-2.15-0.07
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.45-0.570.37-0.640.150.780.00
Cash from Operating Activities-4.64-4.66-5.56-5.63-5.60-1.38-0.07
Capital Expenditures0.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock7.287.603.617.702.864.400.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock7.287.603.617.702.864.400.00
Proceedsfrom Stock Options6.396.713.617.702.864.400.00
Issuance or Reduction of Debt, Net0.000.000.002.11-0.160.200.09
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.240.570.180.070.45-0.42-0.02
Other Financing Activities Uses----0.07--0.43-0.02
Cash from Financing Activities7.528.183.799.883.154.180.07
Net Change in Cash2.883.51-1.774.25-2.462.810.00
Free Cash Flow-4.64-4.66-5.56-5.63-5.60-1.38-0.07
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.119.4111.037.540.731.21
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.050.020.030.060.100.16
Total Current Assets8.179.4311.067.600.831.36
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets8.209.4611.097.630.871.40
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.040.030.130.080.300.10
Other Current Liabilities0.000.080.570.000.000.01
Total Current Liabilities0.040.110.700.080.300.11
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.040.110.700.080.300.11
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.169.3510.397.550.571.29
Total Shareholders Equity8.169.3510.397.550.571.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.169.3510.397.550.571.29
Total Liabilities & Stockholders Equity8.209.4611.097.630.871.40
Book Value Per Share0.190.220.250.190.030.08
Tangible Book Value Per Share0.190.220.250.190.030.08
Full-Time Employees--2---
Price to Book Ratio3.204.327.9041.4915.727.38
Return on Assets-684.27-577.42-456.59-477.58-399.86-304.03
Return on Equity-710.85-589.41-508.28-510.93-556.87-355.82
Return on Invested Capital-14.81-12.30-57.58-300.62-269.84-137.83
Quick Ratio200.0882.1615.7590.532.7912.86
Current Ratio200.0882.1615.7590.532.7912.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.21-1.15-5.98-1.14-1.54-1.78
Other Funds (Non Cash)0.110.204.770.210.490.87
Funds from Operations-1.10-0.95-1.21-0.92-1.05-0.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.11-0.250.08-0.170.25-0.72
Cash from Operating Activities-1.21-1.20-1.14-1.10-0.80-1.63
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.004.273.010.320.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.004.273.010.320.00
Proceedsfrom Stock Options0.000.003.682.710.320.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.330.570.000.000.00
Other Financing Activities Uses0.00-0.33-0.000.000.00
Cash from Financing Activities0.00-0.334.843.010.320.00
Net Change in Cash-1.21-1.533.711.91-0.48-1.63
Free Cash Flow-1.21-1.20-1.14-1.10-0.80-1.63

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.73%0.3M38.7M602.47K
2026-10-150.90%0.3M38.7M580.35K
2026-09-301.06%0.4M38.7M571.01K
2026-09-151.16%0.4M38.7M565.03K
2026-08-310.53%0.2M38.7M83.26K
2026-08-140.55%0.2M38.7M101.68K
2026-07-310.53%0.2M38.7M96.32K
2026-07-150.73%0.3M35.1M116.83K
2026-06-300.54%0.2M35.1M133.24K
2026-06-150.78%0.3M35.1M150.23K
2026-05-291.05%0.4M35.1M161.35K
2026-05-151.16%0.4M35.1M153.69K
2026-04-301.18%0.4M35.1M158.65K
2026-04-151.08%0.4M35.1M156.89K
2026-03-311.25%0.4M35.1M153.38K
2026-03-130.95%0.3M34.9M173.44K
2026-02-271.40%0.5M34.9M176.67K
2026-02-131.63%0.6M34.9M195.23K
2026-01-301.26%0.4M35.0M229.56K
2026-01-150.99%0.3M35.0M2.24M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-288-KCurrent report2026-10-28SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-09-178-KCurrent report2026-09-17SEC
2026-09-168-KCurrent report2026-09-11SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-318-KCurrent report2026-07-27SEC
2026-07-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-28SEC
2026-07-108-KCurrent report2026-07-10SEC
2026-07-068-KCurrent report2026-07-06SEC
2026-06-258-KCurrent report2026-06-25SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-093Initial statement of beneficial ownership of securities2026-06-02SEC
2026-06-088-KCurrent report2026-06-02SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-278-KCurrent report2026-05-21SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-138-KCurrent report2026-05-12SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-30SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-238-KCurrent report2026-03-23SEC
2026-03-038-KCurrent report2026-03-03SEC
2026-02-175Annual statement of changes in beneficial ownership of securities2025-12-31SEC
2026-02-028-KCurrent report2026-02-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.79%
GEODE CAPITAL MANAGEMENT, LLC0.97%
Cross Staff Investments Inc0.86%
BlackRock, Inc.0.58%
VANGUARD FIDUCIARY TRUST CO0.41%
CAPTRUST FINANCIAL ADVISORS0.22%
NORTHERN TRUST CORP0.16%
COMMONWEALTH EQUITY SERVICES, LLC0.16%
First American Bank0.14%
STATE STREET CORP0.12%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.94%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Fidelity Extended Market Index Fund0.35%
iShares Micro-Cap ETF0.30%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.03%
1290 VT Micro Cap Portfolio0.02%
VANGUARD BALANCED INDEX FUND0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. MIRA. Cached 15 minutes.

Some panels did not load: ratings, insider.